Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Heart Rhythm. 2008 Mar 21;5(7):1019–1026. doi: 10.1016/j.hrthm.2008.03.018

Figure 2.

Figure 2

Effects of ranolazine (10 µM) on maximum upstroke velocity of the action potential (Vmax) following an abrupt change in basic cycle length (BCL) in a PV sleeve preparation. Upper panel: Recordings of APs and Vmax following a change in BCL from 2000 to 200 ms (A, control; B, Ranolazine) and from 2000 to 170 ms (C, control; D, Ranolazine). Lower panel: Plot of beat to beat changes in Vmax (E, control; F, Ranolazine).